Dr. Kane is new urology chief at UCSD Medical Center
Christopher Kane, MD, has been appointed the new chief of urology at the University of California, San Diego Medical Center and Moores UCSD Cancer Center.
Christopher Kane, MD, has been appointed the new chief of urology at the University of California, San Diego Medical Center and Moores UCSD Cancer Center.
Dr. Kane is the former vice chair of urology at the University of California, San Francisco, where he was also a member of the UCSF Comprehensive Cancer Center, director of the urologic oncology fellowship, and chief of urology of the VA Medical Center San Francisco.
”Dr. Kane’s recruitment to UC San Diego Medical Center represents the university’s next step in developing a comprehensive, world-class cancer center in Southern California,” said Mark A. Talamini, MD, of the UCSD Medical Center. ”Chris Kane is a true physician-scientist whose discoveries will be applied at the bedside of our cancer patients and will lead to better treatment for all patients seeking innovative care options.”
Dr. Kane, a leader in minimally invasive surgical techniques, has performed more than 300 robotic prostatectomies. He is also an expert in the minimally invasive treatment of kidney cancer and will continue his research at UCSD Medical Center with an in-depth focus on studying and analyzing patient outcomes and on discovering new biologic agents to treat cancer.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
